Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30083950 | 0.81 | TDP1 (0.39) | TDP1NFKB1NFKB2RELADGAT1 | |
| SCHEMBL5709587 | 0.81 | CA1 (0.37) | TDP1NFKB1NFKB2RELADGAT1 | |
| SCHEMBL101218 | 0.80 | DGAT1 (0.46) | TDP1NFKB1NFKB2RELADGAT1 | |
| Potassium SCHEMBL29554503 | 0.78 | DGAT1 (0.44) | TDP1NFKB1NFKB2RELADGAT1 | |
| SCHEMBL6272856 | 0.78 | DGAT1 (0.44) | TDP1NFKB1NFKB2RELADGAT1 | |
| SCHEMBL1522412 | 0.78 | DGAT1 (0.44) | TDP1NFKB1NFKB2RELADGAT1 | |
| SCHEMBL16579901 | 0.77 | CA14 (0.41) | TDP1NFKB1NFKB2RELADGAT1 | |
| SCHEMBL19500078 | 0.77 | L3MBTL1 (0.38) | TDP1NFKB1NFKB2RELADGAT1 | |
| SCHEMBL14661964 | 0.76 | CRBN (0.42) | TDP1NFKB1NFKB2RELADGAT1 | |
| SCHEMBL14949475 | 0.75 | DGAT1 (0.42) | TDP1NFKB1NFKB2RELADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| CN-115572264-B | Enzalu Process for the preparation of amines | 山东新时代药业有限公司 | 2025-12-05 | — | — | CN | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| WO-2007118852-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | WO | disclosed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| US-20060235220-A1 | Dipeptide nitriles | MISSBACH MARTIN | 2006-10-19 | — | — | US | disclosed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| US-20040110806-A1 | Dipeptide derivatives | ALTMANN EVA (CH) | 2004-06-10 | — | — | US | disclosed |
| US-20040029814-A1 | Dipeptide nitriles | ALTMANN EVA (CH) | 2004-02-12 | — | — | US | disclosed |
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | disclosed |
| EP-1028942-A2 | DIPEPTIDE NITRILES | Novartis AG (CH) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024460-A2 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110806-A1 | Dipeptide derivatives | CTSL, CTSZ, CTSS | TDP1 2648/4885NFKB1 544/4885NFKB2 905/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | TDP1 1554/4885NFKB1 3803/4885NFKB2 3883/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | TDP1 505/4885NFKB1 3566/4885NFKB2 3947/4885 |
| US-20070293490-A1 | Quinazoline Derivatives | CCNA1, CCND3, CCND2 | TDP1 659/4885NFKB1 1429/4885NFKB2 1899/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | TDP1 505/4885NFKB1 3566/4885NFKB2 3947/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | TDP1 1504/4885NFKB1 3462/4885NFKB2 3873/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | TDP1 505/4885NFKB1 3566/4885NFKB2 3947/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | TDP1 505/4885NFKB1 3566/4885NFKB2 3947/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | TDP1 453/4885NFKB1 3607/4885NFKB2 4020/4885 |
| US-20040029814-A1 | Dipeptide nitriles | NOS1, CTSL, CTSS | TDP1 2327/4885NFKB1 415/4885NFKB2 687/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | TDP1 505/4885NFKB1 3566/4885NFKB2 3947/4885 |
| US-20060235220-A1 | Dipeptide nitriles | CTSL, CTSS, CTSB | TDP1 2871/4885NFKB1 552/4885NFKB2 633/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | TDP1 505/4885NFKB1 3566/4885NFKB2 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.